免疫检查点CTLA-4、PD-1/PD-L1、VISTA在溃疡性结肠炎中的研究进展
The Research Progress of Immune Checkpoints CTLA-4, PD-1/PD-L1 and VISTA in Ulcerative Colitis
DOI: 10.12677/jcpm.2025.44414, PDF,   
作者: 赵艳革：济宁医学院临床医学院，山东 济宁；王韶轩*：济宁市第一人民医院消化内科，山东 济宁
关键词: 免疫检查点；溃疡性结肠炎；炎症机制；细胞因子；Immune Checkpoints； Ulcerative Colitis； Inflammatory Mechanisms； Cytokines
摘要: 溃疡性结肠炎(Ulcerative Colitis, UC)是一种难治性且容易复发的非特异性的炎症性肠病，主要发生于结直肠。目前认为其发病机制复杂且不明确，针对UC的发病机制尚在研究中，临床上治疗效果也欠佳。通过大量阅读文献，并进行总结发现，新型免疫检查点在溃疡性结肠炎领域的研究具有广阔的前景，需要进一步深入探究免疫检查点之间的相互作用机制，以及它们与其他免疫分子和信号通路之间的复杂关系。通过明确免疫检查点的异常调节如何导致炎症反应和组织损伤等一系列病理过程，进一步完善UC发病机制的理论体系，为后续的基础研究奠定坚实基础，为UC的治疗提供了全新的靶点和策略。
Abstract: Ulcerative colitis (UC), a refractory and relapsing non-specific inflammatory bowel disease primarily affecting the colon and rectum, is characterized by complex and incompletely elucidated pathogenesis. Current clinical therapies remain suboptimal. Extensive literature review suggests that novel immune checkpoints hold promising potential in UC research. Further exploration is warranted to delineate the intricate interplay between immune checkpoints themselves, as well as their interactions with other immune molecules and signaling pathways. Clarifying how dysregulated immune checkpoint activity drives pathological processes, including sustained inflammatory responses and tissue damage, will refine the theoretical framework of UC pathogenesis. This advancement may establish a foundation for future mechanistic studies and provide innovative therapeutic targets and strategies for UC management.
文章引用：赵艳革, 王韶轩. 免疫检查点CTLA-4、PD-1/PD-L1、VISTA在溃疡性结肠炎中的研究进展[J]. 临床个性化医学, 2025, 4(4): 41-48. https://doi.org/10.12677/jcpm.2025.44414

参考文献

[1] Zou, M. and Zhu, Y. (2022) Exploring the Molecular Mechanism of Tong Xie Yao Fang in Treating Ulcerative Colitis Using Network Pharmacology and Molecular Docking. Evidence-Based Complementary and Alternative Medicine, 2022, Article ID: 8141443. [Google Scholar] [CrossRef] [PubMed]
[2] He, J., Zhang, Y., Ouyang, K., Chen, L., Meng, W., Zhang, Y., et al. (2022) Extraction, Chemical Composition, and Protective Effect of Essential Oil from Chimonanthus nitens Oliv. Leaves on Dextran Sodium Sulfate‐Induced Colitis in Mice. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 9701938. [Google Scholar] [CrossRef] [PubMed]
[3] Liu, J., Di, B. and Xu, L. (2023) Recent Advances in the Treatment of IBD: Targets, Mechanisms and Related Therapies. Cytokine & Growth Factor Reviews, 71-72, 1-12. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, J., Jiang, X., Gao, H., Zhang, F., Zhang, X., Zhou, A., et al. (2022) Structural Basis of a Novel Agonistic Anti-Ox40 Antibody. Biomolecules, 12, Article No. 1209. [Google Scholar] [CrossRef] [PubMed]
[5] Pyo, J.Y., Yoon, T., Ahn, S.S., Song, J.J., Park, Y. and Lee, S. (2022) Soluble Immune Checkpoint Molecules in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Scientific Reports, 12, Article No. 21319. [Google Scholar] [CrossRef] [PubMed]
[6] Khadela, A., Shah, Y., Mistry, P., Bodiwala, K. and Cb, A. (2023) Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. Technology in Cancer Research & Treatment, 22. [Google Scholar] [CrossRef] [PubMed]
[7] Massarelli, E., Lam, V.K., Parra, E.R., Rodriguez-Canales, J., Behrens, C., Diao, L., et al. (2019) High OX-40 Expression in the Tumor Immune Infiltrate Is a Favorable Prognostic Factor of Overall Survival in Non-Small Cell Lung Cancer. Journal for ImmunoTherapy of Cancer, 7, Article No. 351. [Google Scholar] [CrossRef] [PubMed]
[8] Puntigam, L.K., Jeske, S.S., Götz, M., Greiner, J., Laban, S., Theodoraki, M., et al. (2020) Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo-and Immunotherapy. International Journal of Molecular Sciences, 21, Article No. 5181. [Google Scholar] [CrossRef] [PubMed]
[9] Lee, J.H., Kim, Y.J., Ryu, H.W., Shin, S.W., Kim, E.J., Shin, S.H., et al. (2023) Correction: B7-H3 Expression Is Associated with High PD-L1 Expression in Clear Cell Renal Cell Carcinoma and Predicts Poor Prognosis. Diagnostic Pathology, 18, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[10] Dong, G., Huang, X., Chen, R., Wu, L., Jiang, S. and Chen, S. (2022) Increased PD-L1 Restricts Liver Injury in Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2022, Article ID: 5954437.
[11] Krzyżanowska, N., Krawczyk, P., Wojas-Krawczyk, K., Kucharczyk, T. and Milanowski, J. (2022) Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy? Cells, 11, Article No. 3280. [Google Scholar] [CrossRef] [PubMed]
[12] Baldanzi, G. (2022) Immune Checkpoint Receptors Signaling in T Cells. International Journal of Molecular Sciences, 23, 3529.
[13] Teft, W.A., Chau, T.A. and Madrenas, J. (2009) Structure-Function Analysis of the CTLA-4 Interaction with PP2A. BMC Immunology, 10, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[14] Kim, G. and Choi, J. (2022) Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy. Molecules and Cells, 45, 513-521. [Google Scholar] [CrossRef] [PubMed]
[15] Sekiya, T. and Takaki, S. (2019) RGMB Enhances the Suppressive Activity of the Monomeric Secreted Form of CTLA-4. Scientific Reports, 9, Article No. 6984. [Google Scholar] [CrossRef] [PubMed]
[16] Li, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., et al. (2019) A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells from Multiple Types of Cancer. Frontiers in Oncology, 9, Article No. 1066. [Google Scholar] [CrossRef] [PubMed]
[17] Lerner, A. and Benzvi, C. (2022) Checkpoint Inhibitors and Induction of Celiac Disease-Like Condition. Biomedicines, 10, Article No. 609. [Google Scholar] [CrossRef] [PubMed]
[18] Abu-Sbeih, H., Faleck, D.M., Ricciuti, B., Mendelsohn, R.B., Naqash, A.R., Cohen, J.V., et al. (2020) Immune Checkpoint Inhibitor Therapy in Patients with Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 38, 576-583. [Google Scholar] [CrossRef] [PubMed]
[19] Chen, X., Dou, J., Fu, Z., Qiu, Y., Zou, L., Huang, D., et al. (2022) Macrophage M1 Polarization Mediated via the IL-6/STAT3 Pathway Contributes to Apical Periodontitis Induced by Porphyromonas gingivalis. Journal of Applied Oral Science, 30, e20220316. [Google Scholar] [CrossRef] [PubMed]
[20] Fear, V.S., Tilsed, C., Chee, J., Forbes, C.A., Casey, T., Solin, J.N., et al. (2018) Combination Immune Checkpoint Blockade as an Effective Therapy for Mesothelioma. OncoImmunology, 7, e1494111. [Google Scholar] [CrossRef] [PubMed]
[21] Li, D., Li, J., Chu, H. and Wang, Z. (2020) A Functional Antibody Cross-Reactive to both Human and Murine Cytotoxic T-Lymphocyte-Associated Protein 4 via Binding to an N-Glycosylation Epitope. mAbs, 12, Article ID: 1725365. [Google Scholar] [CrossRef] [PubMed]
[22] Yamamoto, T. (2022) Skin Manifestation Induced by Immune Checkpoint Inhibitors. Clinical, Cosmetic and Investigational Dermatology, 15, 829-841. [Google Scholar] [CrossRef] [PubMed]
[23] Saha, A., Dreyfuss, I., Sarfraz, H., Friedman, M. and Markowitz, J. (2022) Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis. Cancers, 15, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[24] Ayoub, N.M., Al-Shami, K.M. and Yaghan, R.J. (2019) Immunotherapy for Her2-Positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches. Breast Cancer: Targets and Therapy, 11, 53-69. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., et al. (2020) The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells. Cell Communication and Signaling, 18, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[26] Zhou, X., Li, C., Chen, T., Li, W., Wang, X. and Yang, Q. (2023) Targeting RNA N6-Methyladenosine to Synergize with Immune Checkpoint Therapy. Molecular Cancer, 22, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[27] Feng, P., Wang, X., Ferrall, L., Wu, T.-. and Hung, C. (2022) Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide. Journal of Immunology Research, 2022, Article ID: 9054569. [Google Scholar] [CrossRef] [PubMed]
[28] Li, Y., Cong, Y., Jia, M., He, Q., Zhong, H., Zhao, Y., et al. (2021) Targeting IL-21 to Tumor-Reactive T Cells Enhances Memory T Cell Responses and Anti-PD-1 Antibody Therapy. Nature Communications, 12, Article No. 951. [Google Scholar] [CrossRef] [PubMed]
[29] Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S., et al. (2020) Mechanisms of Checkpoint Inhibition-Induced Adverse Events. Clinical and Experimental Immunology, 200, 141-154. [Google Scholar] [CrossRef] [PubMed]
[30] Chen, M., Li, C., Sun, M., Li, Y. and Sun, X. (2022) Recent Developments in PD-1/PD-L1 Blockade Research for Gastroesophageal Malignancies. Frontiers in Immunology, 13, Article ID: 1043517. [Google Scholar] [CrossRef] [PubMed]
[31] Aguilera, J., Han, X., Cao, S., Balmes, J., Lurmann, F., Tyner, T., et al. (2022) Increases in Ambient Air Pollutants during Pregnancy Are Linked to Increases in Methylation of IL4, IL10, and IFNγ. Clinical Epigenetics, 14, Article No. 40. [Google Scholar] [CrossRef] [PubMed]
[32] Cairat, M., Rinaldi, S., Navionis, A., Romieu, I., Biessy, C., Viallon, V., et al. (2022) Circulating Inflammatory Biomarkers, Adipokines and Breast Cancer Risk—A Case-Control Study Nested within the EPIC Cohort. BMC Medicine, 20, Article No. 118. [Google Scholar] [CrossRef] [PubMed]
[33] Aghamohammad, S., Sepehr, A., Miri, S.T., Najafi, S., Rohani, M. and Pourshafiea, M.R. (2022) The Effects of the Probiotic Cocktail on Modulation of the NF-κb and JAK/STAT Signaling Pathways Involved in the Inflammatory Response in Bowel Disease Model. BMC Immunology, 23, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[34] Batyrova, B., Luwaert, F., Maravelia, P., Miyabayashi, Y., Vashist, N., Stark, J.M., et al. (2019) PD‐1 Expression Affects Cytokine Production by ILC2 and Is Influenced by Peroxisome Proliferator‐Activated Receptor‐γ. Immunity, Inflammation and Disease, 8, 8-23. [Google Scholar] [CrossRef] [PubMed]
[35] Shi, W., Zhang, Y., Hao, C., Guo, X., Yang, Q., Du, J., et al. (2023) The Significance of PD-1/PD-L1 Imbalance in Ulcerative Colitis. PeerJ, 11, e15481. [Google Scholar] [CrossRef] [PubMed]
[36] Wang, F., Song, J., Yan, Y., Zhou, Q., Li, X., Wang, P., et al. (2022) Correction to “Integrated Network Pharmacology Analysis and Serum Metabolomics to Reveal the Antimalaria Mechanism of Artesunate”. ACS Omega, 7, Article No. 36047. [Google Scholar] [CrossRef] [PubMed]
[37] Amatore, F., Ortonne, N., Lopez, M., Orlanducci, F., Castellano, R., Ingen-Housz-Oro, S., et al. (2020) ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma, and Its Targeting Promotes Potent Killing of Malignant Cells. Blood Advances, 4, 5203-5214. [Google Scholar] [CrossRef] [PubMed]
[38] Tian, J., Zhu, Q., Zhang, Y., Bian, Q., Hong, Y., Shen, Z., et al. (2020) Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Experimental Colitis via Modulating Th1/Th17 and Treg Cell Responses. Frontiers in Immunology, 11, Article ID: 598322. [Google Scholar] [CrossRef] [PubMed]
[39] Kim, M.K., Jo, S.I., Kim, S., Lim, H., Kang, H.S., Moon, S., et al. (2023) Pd-1-Positive Cells Contribute to the Diagnosis of Inflammatory Bowel Disease and Can Aid in Predicting Response to Vedolizumab. Scientific Reports, 13, Article No. 21329. [Google Scholar] [CrossRef] [PubMed]
[40] Tagliamento, M., Agostinetto, E., Borea, R., Brandão, M., Poggio, F., Addeo, A., et al. (2021) VISTA: A Promising Target for Cancer Immunotherapy? ImmunoTargets and Therapy, 10, 185-200. [Google Scholar] [CrossRef] [PubMed]
[41] Hosseinkhani, N., Derakhshani, A., Shadbad, M.A., Argentiero, A., Racanelli, V., Kazemi, T., et al. (2021) The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Frontiers in Immunology, 12, Article ID: 676181. [Google Scholar] [CrossRef] [PubMed]
[42] Tang, X., Xiong, Y., Shi, X., Zhao, Y., Shi, A., Zheng, K., et al. (2022) IGSF11 and VISTA: A Pair of Promising Immune Checkpoints in Tumor Immunotherapy. Biomarker Research, 10, Article No. 49. [Google Scholar] [CrossRef] [PubMed]
[43] Mehta, N., Maddineni, S., Mathews, I.I., Andres Parra Sperberg, R., Huang, P. and Cochran, J.R. (2019) Structure and Functional Binding Epitope of V-Domain Ig Suppressor of T Cell Activation. Cell Reports, 28, 2509-2516.e5. [Google Scholar] [CrossRef] [PubMed]
[44] Emaldi, M., Alamillo-Maeso, P., Rey-Iborra, E., Mosteiro, L., Lecumberri, D., Pulido, R., et al. (2024) A Functional Role for Glycosylated B7-H5/VISTA Immune Checkpoint Protein in Metastatic Clear Cell Renal Cell Carcinoma. iScience, 27, Article ID: 110587. [Google Scholar] [CrossRef] [PubMed]
[45] ElTanbouly, M.A., Zhao, Y., Nowak, E., Li, J., Schaafsma, E., Le Mercier, I., et al. (2020) VISTA Is a Checkpoint Regulator for Naïve T Cell Quiescence and Peripheral Tolerance. Science, 367, eaay0524. [Google Scholar] [CrossRef] [PubMed]
[46] Xu, W., Dong, J., Zheng, Y., Zhou, J., Yuan, Y., Ta, H.M., et al. (2019) Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunology Research, 7, 1497-1510. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, S., Su, W., Wu, X. and Dong, W. (2024) Restoring Treg/Th17 Cell Balance in Ulcerative Colitis through HRas Silencing and MAPK Pathway Inhibition. International Immunopharmacology, 130, Article ID: 111608. [Google Scholar] [CrossRef] [PubMed]
[48] Zhang, Y., Li, J. and Yin, X. (2023) High-Expression of Galactosidase Alpha Is Correlated with Poor Prognosis and Immune Infiltration in Low-Grade Glioma. Journal of Cancer, 14, 646-656. [Google Scholar] [CrossRef] [PubMed]
[49] Zheng, M., Zhang, Z., Yu, L., Wang, Z., Dong, Y., Tong, A., et al. (2023) Immune-Checkpoint Protein VISTA in Allergic, Autoimmune Disease and Transplant Rejection. Frontiers in Immunology, 14, Article ID: 1194421. [Google Scholar] [CrossRef] [PubMed]
[50] Vicier, C., Isambert, N., Cropet, C., Hamimed, M., Osanno, L., Legrand, F., et al. (2022) MOVIE: A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Metronomic Vinorelbine Combined with Durvalumab plus Tremelimumab in Patients with Advanced Solid Tumors. ESMO Open, 7, Article ID: 100646. [Google Scholar] [CrossRef] [PubMed]
[51] Xu, J., Cen, X., Yao, Y., Zhao, S., Li, W., Zhang, W., et al. (2022) Identification of Six N7-Methylguanosine-Related miRNA Signatures to Predict the Overall Survival and Immune Landscape of Triple-Negative Breast Cancer through in Silico Analysis. Journal of Oncology, 2022, Article ID: 2735251. [Google Scholar] [CrossRef] [PubMed]
[52] Zarifa, A., Kim, J.W., Lopez-Mattei, J., Palaskas, N., Iliescu, C. and Kim, P.Y. (2021) Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. Korean Circulation Journal, 51, 579-597. [Google Scholar] [CrossRef] [PubMed]
[53] Cheng, Y., Ling, F., Li, J., Chen, Y., Xu, M., Li, S., et al. (2023) An Updated Review of Gastrointestinal Toxicity Induced by PD-1 Inhibitors: From Mechanisms to Management. Frontiers in Immunology, 14, Article ID: 1190850. [Google Scholar] [CrossRef] [PubMed]
[54] Choi, J.W., Kim, Y.J., Yun, K.A., Won, C.H., Lee, M.W., Choi, J.H., et al. (2020) The Prognostic Significance of VISTA and CD33-Positive Myeloid Cells in Cutaneous Melanoma and Their Relationship with PD-1 Expression. Scientific Reports, 10, Article No. 14372. [Google Scholar] [CrossRef] [PubMed]